Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. Microbiological and Clinical Study Groups.
Three hundred and forty-five clinical isolates from patients treated with cefpirome were studied using an MIC methodology to develop tentative breakpoints for cefpirome, and to correlate clinical success with in-vitro susceptibility. No relationship between elimination, persistence and MIC of potential pathogens was found. There was, however, a close relationship between clinical cure and improvement and eradication of causative organisms. Based on the data, tentative breakpoints of less than 4 mg/L for sensitive and greater than 16 mg/L for resistance, at a cefpirome dose of 2.0 g bid or 1.0 g bid for urinary tract infection, are suggested.
Shah
P M
PM
Johann Wolfgang Goethe University Hospital, Frankfurt, Germany.
Schäfer
V
V
Ziemen
M
M
Krauskopf
S
S
D001419:Bacteria / Q000187:drug effects; D002511:Cephalosporins / Q000627:therapeutic use*; D016983:Enterococcus / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D015337:Multicenter Studies as Topic; D011014:Pneumonia / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*; D000097572:Cefpirome
D002511:Cephalosporins; D000097572:Cefpirome